HER-2 in Gastric/GEJ Adenocarcinoma: TOGA

• Bang et al, Lancet 2010; 376: 687-697
• 594 pts with advanced/metastatic HER2+ gastric/gastroesophageal adenocarcinoma, no prior chemo for metastatic disease enrolled 9/2005-12/2008:
• Primary endpoint: Survival
• Stratified by disease extent, primary site, measurable disease, PS, fluoropyrimidine
• Cisplatin + capecitabine (or 5FU in about 12% of pts) q 3 weeks x 6 cycles, +/- trastuzumab (8 mg/kg IV D#1, then 6 mg/kg q 3 weeks)